Related Experiment Video
Updated: Jul 9, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers
Alberto Mussetti1, Nicole Fabbri2, Anna Sureda1,3
1Department of Hematology, Catalan Institute of Oncology, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Hematology. American Society of Hematology. Education Program
|December 9, 2023
Summary
Identifying prognostic factors before, during, and after anti-CD19 CAR T-cell therapy is key for improving outcomes in relapsed or refractory large B-cell lymphomas. Personalized treatment strategies are essential for patients undergoing this advanced therapy.
Area of Science:
- Oncology
- Immunotherapy
- Hematology
Background:
- Anti-CD19 CAR T-cell therapy offers significant benefits for relapsed or refractory large B-cell lymphomas.
- However, a notable proportion of patients experience relapse after treatment.
Conclusions:
- Prognostic factors span multiple time points in CAR T-cell therapy for large B-cell lymphomas.
- Integrating various factors can guide personalized treatment decisions.
- Clinical trial enrollment is vital for advancing patient outcomes.

